SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and a sharp multi-year price decline following a weak outlook and concerns over declining demand in China. While the community remains deeply divided, with some investors betting on a generational value play due to the brand's iconic status and dividend, others are aggressively shorting the stock, citing poor leadership, brand dilution, and concerns that the company's growth model is fundamentally broken.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid intense community debate over its aggressive Bitcoin-linked treasury strategy, with investors highlighting significant price volatility and concerns regarding share dilution. The conversation is currently split between those betting on long-term institutional adoption and short sellers pointing to structural leverage risks and downward price action.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is experiencing intense volatility and downward pressure as investors debate whether the stock is an oversold growth opportunity or a bubble facing a severe consumer discretionary correction. While bullish participants point to the company's aggressive store expansion, share buybacks, and international potential as reasons to buy the dip, bears are aggressively shorting the stock, citing concerns over same-store sales declines, high valuations, and broader fears of consumer exhaustion impacting the restaurant sector.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is trending due to significant volatility following a quarterly earnings report that featured a revenue beat but a notable miss on earnings expectations, coupled with cautious guidance linked to ongoing tariff pressures and housing market headwinds. Investors are actively debating the stock's future, weighing concerns over debt and luxury spending against potential upside from long-term global expansion and anticipation of favorable legal outcomes regarding trade tariffs.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as investors react to a series of analyst downgrades, a recent activist stake from Jana Partners, and a disconnect between the company's strong cash flow and its depressed valuation. While some retail investors are calling it a value trap due to stagnant performance, others are actively buying the dip, citing its dominant market position and low forward P/E as evidence of a significant buying opportunity.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing intense volatility and social media attention as traders monitor its low-float structure and history of sharp, squeeze-driven price moves. The community is actively debating whether current price action signals a repeat of past parabolic runs, with many focusing on the high cost to borrow, limited share availability, and the potential for a swift short squeeze.

Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. It offers properties for rent to life science, agriculture technology (agtech), and technology tenants. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Alexandria Real Estate Equities Inc.

Alexandria Real Estate is currently drawing significant investor scrutiny as share prices hover near multi-year lows, triggering a divide between those concerned by high debt levels and structural biotech sector headwinds, and contrarian investors who view the current valuation as an extreme dislocation from the company's underlying property portfolio value. The community is actively debating the sustainability of the dividend and monitoring institutional accumulation patterns, with many participants treating the current price action as a deeply oversold opportunity despite the near-term uncertainty.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is gaining significant community attention as a new, pure-play vehicle offering direct exposure to SpaceX and other space exploration companies ahead of anticipated industry milestones. Investors are actively debating the fund's early AUM and liquidity, drawing frequent comparisons to other space-themed ETFs and speculating on potential price momentum as interest in commercial space activity intensifies.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a significant clinical update regarding its Phase 1b trial of rinzimetostat in combination with darolutamide for prostate cancer. While the stock faced an intraday slump due to concerns over safety signals at higher doses, community discussion remains heavily divided between those viewing the selloff as an exaggerated overreaction with upside potential and those concerned about the broader implications for EZH2-targeting drug classes.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as retail investors push a potential short squeeze narrative, fueled by record high short interest and rumors regarding a potential reverse merger with Tether. Traders are also closely monitoring the pending acquisition of Northern Data and the platform's expanded focus on cloud infrastructure as key catalysts for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zai Lab Stock Gains 8% Over Clinical Trial Collaboration With Amgen

(RTTNews) - Shares of Zai Lab Limited (ZLAB) are moving up about 8 percent on Wednesday morning trading after the company announced a global clinical trial collaboration with Amgen Inc. (AMGN) to...

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Labs investigational delta-like ligand 3...

Highline Wealth Partners LLC Sells 4,004 Shares of Amgen Inc. $AMGN

Highline Wealth Partners LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 96.0% during the fourth quarter, according to the company in its most recent disclosure with...

Nisa Investment Advisors LLC Has $55.22 Million Stake in Amgen Inc. $AMGN

Nisa Investment Advisors LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 168,716 shares of the medical research company's stock after buying an additiona...

Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co.

Meyer Handelman Co. reduced its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 119,231 shares of...

Amgen Inc. $AMGN Shares Bought by Moody Lynn & Lieberson LLC

Moody Lynn & Lieberson LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 374.0% in the fourth quarter, according to the company in its most recent disclosure with the...

BTC Capital Management Inc. Sells 4,196 Shares of Amgen Inc. $AMGN

BTC Capital Management Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 38.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,812 shares of the medical research company's stock after sel...

Amgen Inc. (NASDAQ:AMGN) Given Average Rating of "Hold" by Analysts

Shares of Amgen Inc. (NASDAQ:AMGN - Get Free Report) have been assigned a consensus rating of "Hold" from the thirty brokerages that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, fourteen have issued a buy rat...

FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos Use

FDA flags liver injury risk tied to Amgen Tavneos, citing drug-induced liver injury and rare vanishing bile duct syndrome complications.read more...

TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Teva wins FDA approval for Prolia biosimilar Ponlimsi and secures Xolair biosimilar filing review by the FDA and EMA, strengthening its biosimilars push.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

AMGN
AMGEN Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AMGN News

AMGNAMGEN Inc.